← Back to headlines
RBC Capital Sustains Outperform Rating on Wave Life Sciences
RBC Capital has reiterated its 'Outperform' rating for Wave Life Sciences (WVE), indicating a continued positive outlook on the biotechnology company's stock.
12 Apr, 21:18 — 12 Apr, 21:18
Sources
Showing 1 of 1 sources
